Our research
Recent access to virtual libraries containing billions of readily synthesizable compounds has opened novel avenues for early-phase drug discovery. Deploying state-of-the-art machine learning models on Sweden’s powerful supercomputers, we cost-effectively pinpoint the most promising molecules for experimental evaluation. Initial projects in the Luttens lab will focus on the design of potent antibiotics to combat Gram-negative bacteria and developing new drug modalities targeting flaviviruses. At the same time, we are eager to broaden the scope of our research and are actively pursuing exciting collaborations with national and international groups seeking to leverage our experience in computer-assisted drug discovery.